Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$477MCash on Hand
59.8mo Cash Runway
Follow MAZE by emailGet an email when MAZE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MAZE, unsubscribe in one click. Privacy
📣 What MAZE Says Is Next
first half of 2027 · MZE829: “Subject to regulatory feedback, Maze plans to initiate a pivotal trial in the first half of 2027.”
Company press release, Nov 9, 2026 · SEC filing
first half of 2027 · “Maze plans to initiate a Phase 2 proof-of-concept trial of MZE782 evaluating proteinuria reduction in CKD in the first half of 2027.”
Company press release, Nov 9, 2026 · SEC filing
in 2027 · “Topline data from the trial is expected in 2027.”
Company press release, Nov 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Earnings Reported Q3 2026 results: cash and securities of $477.0 million, runway into 2029. Net loss for the quarter was $48.0 million ($0.79 per share). Enrollment completed in Phase 2 HORIZON trial of MZE829, with full data expected early 2027. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 16, 2026 ·
Financing Maze exchanged 2,776,007 common shares held by Frazier Life Sciences funds for pre-funded warrants at $0.001 exercise price, under an October 15, 2026 exchange agreement. Outstanding common stock is 53,931,889 after the exchange. Warrants issued under Section 3(a)(9). Form 8-K · SEC filing
Aug 17, 2026 ·
Leadership Maze appointed Paula Johnson, M.D., M.P.H., as a Class III director and Sophie Kornowski, Pharm.D., as a Class I director, effective August 13, 2026. Each receives an option to buy 36,000 shares. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Earnings Reported Q2 2026 results: cash, equivalents and marketable securities of $494.9 million, with runway into 2029. Net loss was $44.7 million, or $0.76 per share, versus $33.7 million, or $0.77 per share, a year earlier. Q2 R&D expenses rose to $34.9 million. HORIZON data for MZE829 expected late 2026 or early 2027. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 2 · Recruiting · A Study of MZE782 in Adults With PKU Registry primary completion date, not a results date
Sep 2026 · Phase 2 · Recruiting · A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
MAZE holds $477M in cash and short-term investments (as of Sep 30, 2026) and burns about $23.9M/quarter from operations,
an estimated runway of 59.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:22 · Moderate
Cash runway 60 months
ATM program on file since Apr 2026 +15
Shelf registration (S-3ASR, Feb 2026) +10
Share count +14% in a year +7
Raised after last reported balance sheet (Oct 2026) -10
Share count 54,683,345 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MAZE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MAZE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.